MME and Alzheimer disease: Since somatostatin is reduced in AD brain and in CSF of AD patients [38,39], one can speculate that this reduction contributes to Aβ deposition in the AD brain through impaired microglial phagocytosis along with the previously described negative influence on Aβ degradation by neprilysin [40].